Research progress of biomarkers for non-small cell lung cancer
- VernacularTitle:非小细胞肺癌生物标志物的研究进展
- Author:
Ziqiang HONG
1
;
Dacheng JIN
2
;
Xiangdou BAI
1
;
Baiqiang CUI
1
;
Yunjiu GOU
2
Author Information
1. 1. The First Clinical Department of Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, P. R. China 2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China
2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China
- Publication Type:Journal Article
- Keywords:
Biomarker;
non-small cell lung cancer;
targeted therapy;
immunotherapy;
diagnosis;
prognosis;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(02):311-318
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been improved significantly. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. At present, molecular biomarkers are becoming a powerful tool for diagnosing cancer, predicting treatment response outcomes, and assessing prognosis. In this review, we summarized the biomarkers relevant to the diagnosis, prediction, and prognosis of NSCLC as well as promising novel predictive biomarkers in the future.
